149 related articles for article (PubMed ID: 38055066)
1. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer.
Tsunematsu M; Uwagawa T; Onda S; Shirai Y; Okui N; Matsumoto M; Furukawa K; Haruki K; Ishizaki S; Ikegami T
Support Care Cancer; 2023 Nov; 31(12):732. PubMed ID: 38055066
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study.
Iwai N; Sakai H; Oka K; Sakagami J; Okuda T; Hattori C; Taniguchi M; Hara T; Tsuji T; Komaki T; Kagawa K; Doi T; Ishikawa T; Yasuda H; Itoh Y
Support Care Cancer; 2023 Jan; 31(2):115. PubMed ID: 36640181
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of anamorelin among patients with diabetes.
Ando K; Naito T; Hamauchi S; Miura K; Nishibori Y; Tonsho A; Matsuda S; Morita M; Sekikawa M; Doshita K; Kodama H; Yabe M; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ryo K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Yamazaki K; Takahashi T
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38722487
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia.
Takeda T; Sasaki T; Okamoto T; Ishitsuka T; Yamada M; Nakagawa H; Mie T; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Intern Med; 2023 Jul; 62(13):1887-1893. PubMed ID: 36418096
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ
Nakanishi Y; Higuchi J; Honda N; Komura N
Nihon Yakurigaku Zasshi; 2021; 156(6):370-381. PubMed ID: 34719572
[TBL] [Abstract][Full Text] [Related]
6. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Wakabayashi H; Arai H; Inui A
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):14-16. PubMed ID: 33382205
[TBL] [Abstract][Full Text] [Related]
7. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.
Ikuta S; Aihara T; Yamanaka N
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e109-e114. PubMed ID: 30632282
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Naito T; Uchino J; Kojima T; Matano Y; Minato K; Tanaka K; Mizukami T; Atagi S; Higashiguchi T; Muro K; Takayama K; Furuse J; Morishima E; Takiguchi T; Tamura K
Cancer; 2022 May; 128(10):2025-2035. PubMed ID: 35195274
[TBL] [Abstract][Full Text] [Related]
9. Does Preoperative Serum Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR) Predict Prognosis Following Radical Surgery for Pancreatic Adenocarcinomas? Results of a Retrospective Study.
Gupta V; Chaudhari V; Shrikhande SV; Bhandare MS
J Gastrointest Cancer; 2022 Sep; 53(3):641-648. PubMed ID: 34406625
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
Karan C; Yaren A; Demirel BC; Dogan T; Ozdemir M; Demiray AG; Taskoylu BY; Degirmencioglu S; Dogu G; Ozhan N; Cakiroglu U; Celikyurek A
Cancer Diagn Progn; 2023; 3(6):706-715. PubMed ID: 37927800
[TBL] [Abstract][Full Text] [Related]
11. Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade.
Neumann CCM; Schneider F; Hilfenhaus G; Vecchione L; Felsenstein M; Ihlow J; Geisel D; Sander S; Pratschke J; Stintzing S; Keilholz U; Pelzer U
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190296
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Neutrophil-Lymphocyte Ratio (NLR)-Binding Fibrinogen-Albumin Ratio (FAR) Is Superior to Platelet-Lymphocyte Ratio (PLR)-Binding Fibrinogen-Albumin Ratio (FAR) and Lymphocyte-Monocyte (LMR)-Binding Fibrinogen-Albumin Ratio (FAR) as Predictors of Survival in Surgical Patients with Colorectal Adenocarcinoma.
Zhao X; Zhou Y; Liu B; Shen Y; Qian J; Zhang X; Zhao H
Med Sci Monit; 2023 Mar; 29():e939442. PubMed ID: 36992543
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
Qi Q; Geng Y; Sun M; Wang P; Chen Z
Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
[TBL] [Abstract][Full Text] [Related]
14. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
[TBL] [Abstract][Full Text] [Related]
15. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.
Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY
Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852
[TBL] [Abstract][Full Text] [Related]
16. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
17. Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database.
Ohta H; Horii T; Yasu T
Oncology; 2023; 101(12):782-785. PubMed ID: 37579746
[TBL] [Abstract][Full Text] [Related]
18. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
Temel JS; Abernethy AP; Currow DC; Friend J; Duus EM; Yan Y; Fearon KC
Lancet Oncol; 2016 Apr; 17(4):519-531. PubMed ID: 26906526
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
20. The Association of the Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio and Systemic Inflammation Response Index with Short-Term Functional Outcome in Patients with Acute Ischemic Stroke.
Zhang YX; Shen ZY; Jia YC; Guo X; Guo XS; Xing Y; Tian SJ
J Inflamm Res; 2023; 16():3619-3630. PubMed ID: 37641703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
